Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $44.00

Castle Biosciences (NASDAQ:CSTL) had its price target increased by Robert W. Baird from $41.00 to $44.00 in a report issued on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages also recently weighed in on CSTL. BTIG Research raised their price objective on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, February 2nd. KeyCorp reaffirmed an “overweight” rating and set a $50.00 price objective on shares of Castle Biosciences in a report on Thursday, January 29th. Finally, Guggenheim raised their target price on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.57.

Castle Biosciences Stock Down 7.2%

CSTL stock opened at $29.57 on Friday. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. Castle Biosciences has a 1 year low of $14.59 and a 1 year high of $44.28. The company has a fifty day simple moving average of $37.17 and a 200 day simple moving average of $31.30. The firm has a market cap of $879.12 million, a PE ratio of -34.79 and a beta of 1.09.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The firm had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. Sell-side analysts anticipate that Castle Biosciences will post 0.44 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 817 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total value of $31,037.83. Following the sale, the insider directly owned 83,698 shares in the company, valued at $3,179,687.02. This trade represents a 0.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Kristen M. Oelschlager sold 14,888 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total transaction of $585,247.28. Following the transaction, the chief operating officer owned 12,323 shares in the company, valued at approximately $484,417.13. The trade was a 54.71% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 29,617 shares of company stock worth $1,167,887. 7.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Castle Biosciences

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after buying an additional 27,511 shares in the last quarter. RTW Investments LP bought a new stake in shares of Castle Biosciences in the 4th quarter worth approximately $82,283,000. Principal Financial Group Inc. lifted its position in shares of Castle Biosciences by 0.7% in the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after acquiring an additional 13,289 shares during the period. Portolan Capital Management LLC grew its holdings in shares of Castle Biosciences by 1.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock worth $34,499,000 after purchasing an additional 25,539 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after purchasing an additional 96,084 shares during the period. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 revenue guide: Castle reported FY2025 revenue of $344M (above guidance) with Q4 revenues roughly in line with estimates and beat on EPS (Q4 GAAP EPS -$0.08 vs. consensus -$0.23). Management set 2026 revenue guidance of $340–$350M (slightly above the prior consensus ~$335M), supporting near‑term top‑line growth expectations. Castle Biosciences outlines 2026 revenue target
• Positive Sentiment: Product momentum and new launch: Core test reports (DecisionDx‑Melanoma and TissueCypher) rose ~37% in 2025 (TissueCypher +86%), and Castle launched AdvanceAD‑Tx (limited access), which expands the addressable market in atopic dermatitis. These operational wins support longer‑term growth potential. Earnings press release
• Positive Sentiment: Analyst upgrade / price target lift: Robert W. Baird raised its price target to $44 and reiterated an Outperform rating, signaling bullish analyst sentiment and implying notable upside from current levels. Baird raises target
• Neutral Sentiment: Additional coverage & materials: Earnings and investor materials (call transcript, slide deck) are available for deeper due diligence — useful for active investors reviewing guidance detail and management commentary. Press release & slide deck
• Neutral Sentiment: Street view: Recent coverage shows a generally constructive analyst stance (average “Moderate Buy” / multiple buy/outperform ratings), which can support sentiment if fundamentals hold. Analyst ratings roundup
• Negative Sentiment: Profitability and accounting headwinds: Despite revenue growth, Castle reported a GAAP net loss for 2025 of $24.2M (vs. net income in 2024) and adjusted EBITDA declined materially (from $75M to $44M). A one‑time acceleration of amortization (IDgenetix) and other items reduced margins — a drag on near‑term earnings power. Zacks earnings summary
• Negative Sentiment: Insider selling and discontinued tests: Public filings and summaries show heavy insider sales in recent months and the discontinuation of IDgenetix (lost volume), both of which can pressure sentiment and raise governance/operational questions for investors. Quiver / results summary

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.